Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)

The summary for the Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)
	CFDA Number:	93.393
	CFDA Description:	Cancer Cause and Prevention Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-CA-10-001
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Oct 26, 2009
	Creation Date:	Oct 26, 2009
	Original Closing Date for Applications:	Sep 30, 2010
	Current Closing Date for Applications:	Sep 30, 2010
	Archive Date:	Oct 31, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$1,500,000
	Federal Grant Award Ceiling:	$200,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of cancer-relevant technologies that address the issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or its derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to have a potential to accelerate and/or enhance the research in cancer biology, prevention, diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen and/or sample quality. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental (R21) grant mechanism, and runs parallel with a FOA of identical scientific scope, RFA-CA-10-002, that solicits applications under the NIH R33 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $1,500,000 to this FOA in fiscal year 2010 to fund up to seven applications in response to this FOA. Budget and Project Period. The total project period for an application submitted in response to this FOA may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-10-001.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Alliance of Glycobiologists for Detection of Cancer (U01); • Cancer Target Discovery and Development (CTDD) Network (U01); • Community Clinical Oncology Program Research Bases (U10); • Minority-Based Community Clinical Oncology Program Groups (U10); • Community Clinical Oncology Program Groups (U10); • Pilot Studies in Pancreatic Cancer; • CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM; • MOLECULAR TARGETS FOR NUTRIENTS IN PROSTATE CANCER PREVENTION; • Cancer Prevention Research Small Grant Program (R03); • Pilot Studies in Pancreatic Cancer (R03)